Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

OLAPARIB for Hormone-refractory prostate cancer: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 313 adverse event reports in the FDA FAERS database where OLAPARIB was used for Hormone-refractory prostate cancer.

Most Reported Side Effects for OLAPARIB

Side Effect Reports % Deaths Hosp.
Death 4,378 24.0% 4,377 104
Malignant neoplasm progression 1,862 10.2% 368 180
Nausea 1,582 8.7% 129 301
Anaemia 1,455 8.0% 205 469
Fatigue 1,437 7.9% 101 241
Off label use 777 4.3% 212 126
Vomiting 642 3.5% 82 187
Drug ineffective 563 3.1% 67 67
Diarrhoea 514 2.8% 60 131
Asthenia 491 2.7% 51 132
Myelodysplastic syndrome 466 2.6% 114 136
Decreased appetite 450 2.5% 51 121
Disease progression 423 2.3% 56 37
Neuropathy peripheral 411 2.3% 13 38
Haemoglobin decreased 390 2.1% 34 117

Other Indications for OLAPARIB

Ovarian cancer (5,923) Prostate cancer (973) Breast cancer female (667) Breast cancer (643) Ovarian cancer recurrent (515) Pancreatic carcinoma (475) Product used for unknown indication (353) Neoplasm malignant (249) Fallopian tube cancer (224) Ovarian epithelial cancer (219)

Other Drugs Used for Hormone-refractory prostate cancer

ENZALUTAMIDE (8,881) RADIUM RA-223 DICHLORIDE (1,615) ABIRATERONE (1,378) DOCETAXEL (674) LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN (579) DAROLUTAMIDE (553) CABAZITAXEL (524) PREDNISONE (474) APALUTAMIDE (365) LEUPROLIDE (262)

Related Pages

OLAPARIB Full Profile All Hormone-refractory prostate cancer Drugs OLAPARIB Demographics OLAPARIB Timeline